Merck, Inc.
🇺🇸United States
Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)
Phase 3
Completed
- Conditions
- Papillomavirus Infections
- Interventions
- Biological: Gardasil™Biological: Placebo
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2016-02-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 176
- Registration Number
- NCT00157950
Osteoporosis Disease Management Demonstration Project (0000-040)
Not Applicable
Completed
- Conditions
- Osteoporosis
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 230
- Registration Number
- NCT00145067
Comparison of Osteoporosis Disease Management Strategies (0000-039)
Not Applicable
Completed
- Conditions
- Osteoporosis
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2015-11-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 4685
- Registration Number
- NCT00145080
A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)
Phase 4
Terminated
- Conditions
- Adenomatous Polyposis Coli
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2019-09-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 62
- Registration Number
- NCT00140894
A Study to Evaluate Rofecoxib Versus Placebo and Diclofenac in Patients With Acute Painful Rotator Cuff Syndrome
Phase 3
Terminated
- Conditions
- Pain
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2006-12-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 274
- Registration Number
- NCT00140933
- Locations
- 🇫🇷
Laboratoires Merck Sharp & Dohme - Chibret, Paris Cedex 8, France
A Study of Rofecoxib in the Treatment of Post-Operative Pain After Total Knee Joint Replacement (0966-259)
Phase 4
Terminated
- Conditions
- Pain
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 11
- Registration Number
- NCT00140920
Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272)
Phase 4
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2017-03-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 255
- Registration Number
- NCT00139932
Osteoporosis Disease Management Demonstration Project (0000-037)
Not Applicable
Completed
- Conditions
- Osteoporosis
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2016-04-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 10000
- Registration Number
- NCT00139425
Improving Management of Patients at High Risk for Osteoporotic Fractures (0000-038)
Not Applicable
Completed
- Conditions
- Osteoporosis
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2016-04-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 4266
- Registration Number
- NCT00139438
A Study of Denufosol Tetrasodium Intravitreal Injection in Subjects With Post Cataract Extraction Macular Edema
Phase 2
Withdrawn
- Conditions
- Macular Edema, Cystoid
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2013-05-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT00135655
© Copyright 2025. All Rights Reserved by MedPath